Business Wire

Adva Network Security achieves BSI approval for PQC-encrypted edge networking device

Share

Adva Network Security today announced that the FSP 150-XG118Pro (CSH) 10Gbit/s edge device now delivers quantum-safe encryption based on post-quantum cryptography (PQC). This enhancement enables operators of critical network infrastructure (CNI) to secure data in motion and build future-ready networks. Certified by the German Federal Office for Information Security (BSI), the solution’s Ethernet encryption offers PQC crypto-agility via a software update, eliminating the need for hardware changes. With its new capabilities, the FSP 150-XG118Pro (CSH) is ideally suited for diverse high-security environments, ranging from national infrastructure to enterprise networks that require strict compliance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203626212/en/

Adva Network Security’s technology is helping operators develop long-term strategies to keep critical network infrastructure safe and secure.

“The threat of quantum computing is reshaping the security landscape and organizations responsible for CNI need clarity, confidence and a clear path forward,” said Michael Roth, GM of Adva Network Security. “By combining BSI approval with quantum-safe encryption in an easily deployable edge device, we’re giving customers a trusted foundation for long-term protection. Our solution is built for agility, enabling security to evolve as threats change and standards advance. This is about future readiness – delivering security that adapts to the evolving threat environment while keeping operations simple, compliant and resilient. We’re ensuring CNI has the protection it needs, not just for today but for decades ahead.”

Part of the Adtran FSP 150 programmable demarcation and edge compute portfolio, the FSP 150-XG118Pro (CSH) delivers quantum-safe encryption using the NIST-standardized ML-KEM algorithm, combined with Diffie-Hellman for dual-layer protection. The device integrates hardware-based encryption, MACsec, precise timing and tamper detection in a temperature-hardened 1RU design. Its crypto-agile architecture supports the rapid adoption of future PQC standards and unifies service demarcation, aggregation, synchronization and network functions virtualization, including routers, firewalls and SD-WAN, on a single platform. With BSI and NATO clearance, it’s trusted to transport VS-NfD and NATO RESTRICTED data in high-security applications.

“Quantum-safe networking marks a turning point for the security of CNI,” commented Josef Sißmeir, GM of Adva Network Security. “As quantum threats move from theory to reality, we’re proud to lead the industry in delivering practical, certified solutions that help organizations stay ahead of the curve. By bringing PQC to the edge, we’re enabling agencies and enterprises to safeguard their most sensitive information and maintain operational resilience for years to come. This milestone is a testament to our commitment to innovation and trust, and we believe it sets a new standard for secure, future-ready networks worldwide.”

About Adva Network Security

Adva Network Security is a leading German IT-security company. We provide robust optical and Ethernet networking solutions and a comprehensive service offering. Our ConnectGuard™ technology delivers quantum-safe encryption that protects large-scale networks and essential applications. Critical infrastructure, government, defense and enterprise customers rely on our technical expertise in communication networks and information security. This unique combination of skills ensures the resilience and security of their essential IT and OT infrastructure. Customers can count on our services team from initial design to secure operation, ensuring business continuity amid growing cyber threats. Our design, manufacturing processes and security solutions are certified by leading government security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by 
Adva Network Security GmbH, Berlin, Germany 
www.advasecurity.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203626212/en/

Contacts

For media
Antje Hartmann
t +49 30 2636969166
info@advasecurity.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

360Learning Integrates With UKG to Transform Enterprise Learning Experiences3.12.2025 15:00:00 EET | Press release

360Learning, the AI-powered collaborative learning platform that combines LMS and LXP capabilities to scale skills development for mid-size and enterprise companies, has announced the integration of its learning platform with UKG's industry-leading workforce operating platform. The partnership empowers companies to accelerate skills-based learning across every level of the organisation, from frontline employees to corporate teams and external partners. Through this integration, UKG Pro and UKG Ready customers can now leverage 360Learning’s comprehensive Learning Management System (LMS) and Learning Experience Platform (LXP) to address employee development and upskilling learning needs, as well as external training for customers and partners. With 360Learning, they’ll have access to the leading AI-powered content authoring tool, dramatically reducing course creation time. Benjamin Marchal, CEO at 360Learning, said: "Our integration with UKG makes it easier for organisations to connect l

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides3.12.2025 15:00:00 EET | Press release

Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible individuals, and implementation varies between countries. The model concept was initiated as part of Owkin’s ongoing partnership with Gustave Roussy and Centre Léon Bérard through PortrAIt, a French consortium dedicated to advancing precision medicine with AI-enabled digital pathology. Fostered through collaboration with AstraZeneca, as announced in October 2024, the development of BRCAura aims to accelerate and expand identification of BRCA mutations in patients with breast cancer. Strong validation across internationa

Winchester Interconnect Launches LiteSPEed ™ Cable: Faster, Lighter, Simpler Connectivity for Mission-Critical Systems3.12.2025 15:00:00 EET | Press release

Winchester Interconnect, an Aptiv company and leading supplier of high-performance interconnect solutions, today introduced LiteSPEed™ Cable, a next-generation single-pair Ethernet (SPE) solution that delivers 10-gigabit data rates in a dramatically smaller, lighter design. Built for the increasingly connected and space-constrained environments of aerospace, defense, industrial automation and next-generation mobility, LiteSPEed™ helps customers move more data with less cable, reducing weight, complexity, and cost while increasing system performance and reliability. “As systems become more intelligent and interconnected, engineers need lighter, more efficient ways to deliver power and data,” said Juan Contreres, director of product management. “LiteSPEed™ gives them a rugged, high-speed Ethernet solution that simplifies installation without compromising performance.” With advanced sensors, real-time analytics, and distributed control systems proliferating across industries, cabling has

Meiji Seika Pharma Invests in Lyric Bio for Next-Generation Human Immunoglobulin Manufacturing3.12.2025 15:00:00 EET | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Toshiaki Nagasato) today announced a strategic equity investment in Lyric Bio, Inc. (Head Office: San Carlos, USA, founded by Chief Executive Officer: Kayj Shannon and Chief Scientific Officer Melanie Matheu). Through this investment, Meiji Seika Pharma seeks to accelerate the early-stage development of Lyric Bio’s innovative platform for producing human immunoglobulin (IVIg), explore donation-independent manufacturing methods, and lay the groundwork for a more resilient, high-quality supply of plasma-derived therapeutics to meet increasing global demand. Lyric Bio is developing a next-generation biomanufacturing platform for IVIg production. The company’s approach uses tissue-mimicking bioreactors built on a proprietary laser-printed cellular substrate that enables ultra high-density cell growth and has the potential to deliver more than 1,000 IVIg doses from a single donor. This investment will accelerate Lyric Bio

ViaLase Announces First Patient Treated in IDE Clinical Trial Evaluating Its Femtosecond Laser Trabeculotomy for Open-Angle Glaucoma3.12.2025 15:00:00 EET | Press release

ViaLase, Inc., a clinical-stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) clinical trial evaluating the company’s femtosecond laser trabeculotomy procedure for the management of glaucoma, a lifelong, progressive, and incurable disease that remains a leading cause of irreversible blindness worldwide. This prospective, multicenter, randomized, controlled trial evaluates the ViaLase procedure in comparison to selective laser trabeculoplasty (SLT), the current standard laser treatment for reducing intraocular pressure (IOP). This trial was designed in consultation with the FDA to achieve clearance and commercialization in the U.S. and thus represents one of the most rigorous evaluations of an incision-free approach to reduce IOP. “Treating the first patient in this trial is a significant milestone, not only for ViaLase, but for the broade

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye